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Prostaglandin E2 and T cells: friends or foes?
Vinatha Sreeramkumar, Manuel Fresno and Natalia Cuesta
Our understanding of the key players involved in the differential regulation of T-cell responses during inflammation, infection
and auto-immunity is fundamental for designing efficient therapeutic strategies against immune diseases. With respect
to this, the inhibitory role of the lipid mediator prostaglandin E2 (PGE2) in T-cell immunity has been documented since the
1970s. Studies that ensued investigating the underlying mechanisms substantiated the suppressive function of micromolar
concentrations of PGE2 in T-cell activation, proliferation, differentiation and migration. However, the past decade has seen a
revolution in this perspective, since nanomolar concentrations of PGE2 have been shown to potentiate Th1 and Th17 responses
and aid in T-cell proliferation. The understanding of concentration-specific effects of PGE2 in other cell types, the development
of mice deficient in each subtype of the PGE2 receptors (EP receptors) and the delineation of signalling pathways mediated by
the EP receptors have enhanced our understanding of PGE2 as an immune-stimulator. PGE2 regulates a multitude of functions
in T-cell activation and differentiation and these effects vary depending on the micro-environment of the cell, maturation
and activation state of the cell, type of EP receptor involved, local concentration of PGE2 and whether it is a homeostatic
or inflammatory scenario. In this review, we compartmentalize the various aspects of this complex relationship of PGE2 with
T lymphocytes. Given the importance of this molecule in T-cell activation, we also address the possibility of using EP receptor
antagonism as a potential therapeutic approach for some immune disorders.
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BIOSYNTHESIS AND FUNCTION OF PROSTANOIDS
Lipid mediators have long been considered as regulators of homeostasis
and inflammation. These molecules are usually produced by a conserved
biosynthetic pathway controlled by specific enzymes that exert their
sequential action on lipid precursors that are released from the plasma
membrane. One of the most important families of lipid mediators is the
prostanoid family, comprises prostaglandins (PGs) and thromboxanes
(Txs).1 The precursor molecule for prostanoids is Arachadonic acid.
Arachadonic acid is released from the plasma membrane phospho-
lipids by the action of phospholipase A2, and is further processed by
cyclooxygenase (COX) enzymes COX-1 and COX-2.2 COX-1 is consti-
tutive and has a role in the maintenance of homeostasis and normal
physiology. COX-1 is expressed in most tissues and is responsible for
the production of ‘housekeeping’ PGs that control normal physio-
logical processes. On the other hand, COX-2 is inducible and can be
activated by a variety of pro-inflammatory stimuli, especially during
infection and inflammation.3,4 Both COX-1 and COX-2 activation
results in the generation of PGG2, which is then reduced to the
intermediate PGH2 via a separate peroxidase site. Various specific
isomerases and oxidoreductases convert PGH2 to the different types of
PGs, such as PGE2, PGI2, PGD2 and PGF2a and additionally TXA2.
5
Most PGs act as potent pro-inflammatory mediators, thereby
making it a desirable therapeutic goal for the treatment of cancer,
rheumatoid arthritis, intestinal inflammation, Alzheimer’s disease and
chronic musculoskeletal pain.6 However, some PGs may exert anti-
inflammatory actions.7
PGE2: SYNTHESIS, FUNCTION AND IMPORTANCE
The isomerization of PGH2 to PGE2 is catalyzed by three different
PGE synthases, namely cytosolic PGE synthase and two membrane-
bound PGE synthases, mPGES-1 and mPGES-2. Cytosolic PGE
synthase and mPGES-2 are constitutive, whereas mPGES-1 is mainly
induced. It is postulated that cytosolic PGE synthase uses PGH2
produced by COX-1, whereas mPGES-1 uses COX-2-derived PGH2.
mPGES-2 can use both sources of PGH2.
8,9 mPGES-1 is upregulated
in response to various pro-inflammatory and mitogenic stimuli with
a concomitantly increased expression of COX-2. Cytokines such as
interleukin (IL)-1b and tumor necrosis factor-a and Toll-like recep-
tor 4 signalling activated by lipopolysaccahride are defined as some
of the inducers of m-PGES-1.10,11 Results obtained from m-PGES-1
knockout mice suggest that this enzyme has key roles in normal
physiology and pathological conditions such as inflammation, pain,
fever, arthritis, stroke, atherosclerosis and cancer,9 hence making it an
innovative therapeutic target.
PGE2 is the most abundant prostanoid found in the human body. It
has many important functions in physiology and is ubiquitously
produced in pathophysiological conditions.3,12,13 This molecule
stereo-specifically exerts potent tissue- and cell type-selective
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actions.14,15 The biological functions of PGE2 range from effects on
the reproductive, gastro-intestinal, immune, cardiovascular and ner-
vous systems. PGE2 has been implicated in multiple physiological
processes mainly because of its ability to induce vasodilation or
vasoconstriction.16 This is especially important in processes such as
embryo implantation, modulation of hemodynamics in kidney, blood
pressure control, childbirth and gastro-intestinal motility. Apart from
these functions, PGE2 has been shown to be a key player in regulating
body temperature and sleep–wake mechanisms and gastrointestinal
secretion along with mucosal barrier functions.16,17 In the field of
tumor biology, COX-2 overexpression leads to increased levels of
PGE2 and has been associated particularly with colorectal, pancreatic,
lung and breast cancer.18 PGE2 has been implicated in tumor
progression through stimulation of angiogenesis, cell invasion and
metastasis, and promotes cell survival by inhibiting apoptosis via
numerous signalling pathways.19,20 Besides, PGE2 also has a role in
tumor evasion of immunosurveillance and has been known to alter
cytokine expression profiles of dendritic cells (DCs) in order to
suppress antitumor cytotoxic T cells.21,22 PGE2-secreting cancer cells
have been shown to induce human Treg cell formation and increase
their inhibitory activity against Th cells that are specific for tumors.23
It is in the area of inflammation that PGE2’s actions are most diverse.
Over the past decades, extensive research using COX-2, m-PGES1 and
EP receptor knockout mice yielded novel and important findings
proving that prostanoids exert both pro-inflammatory and anti-
inflammatory effects, and that these actions are often produced
through directed regulation of gene expression in relevant tissues.
PGE2 usually serves as an important pro-inflammatory mediator
that is involved in the production of all cardinal signs of inflam-
mation: edema, redness, swelling and pain.3,24 This is produced as
a result of the effect of PGE2 on increased microvascular perme-
ability, increase in blood flow to the inflamed site, hyperalgesia
and action on peripheral sensory neurons within the affected area.25
The effect of PGE2 on immune cell types is much more complex.
Apart from favoring the production of inflammation, PGE2 has been
proved to favor DC maturation, antigen uptake and homing to
lymph nodes.26,27 In addition, it has been also demonstrated that
PGE2 can induce the expression of co-stimulatory molecules on DCs,
thus augmenting T-cell activation.28 In macrophages, PGE2 acts as
a positive aid in macrophage activation by interferon (IFN)-g and
tumor necrosis factor-a via its capacity to modulate intracellular cyclic
adenosine monophosphate (cAMP) levels.29 It has also been shown
to be an inducer of matrix metallo-proteinases MMP-2 and MMP-9
in macrophages.30
However, there have been a large number of reports that compile
evidence supporting the notion that PGE2 acts also as an anti-
inflammatory molecule that dampens the immune response (reviewed
in Smyth et al.4). PGE2 has been demonstrated to suppress Th1 differ-
entiation, B-cell functions, T-cell activation and allergic reactions.3,31
Furthermore, PGE2 can exert anti-inflammatory actions on innate
immune cells like neutrophils, monocytes and natural killer cells.3,31
However, the past decade has seen a revolution in the outlook of
PGE2 as a T-cell immunosuppressor, owing to different reports that
substantiate a beneficial role of PGE2 in T-cell differentiation and
immune functions, as discussed in the later sections of this review.
PGE2 RECEPTORS: THE EP RECEPTORS (1–4)
PGE2 binds to four specific G-protein-coupled receptors termed EP
receptors (EP1–4). EP receptors are distinguished by the signal trans-
duction pathway that is activated upon ligand binding.32 Some of the
signalling pathways that are generated by PGE2 are under the control of
the secondary messenger cAMP. cAMP is derived from adenosine
triphosphate by 1 of at least 10 currently identified isoforms of the
adenylyl cyclase (AC) enzymes (AC 1–9 and soluble AC), which differ in
cell-specific expression, regulation and effects, providing an intracellular
system suited for finely targeted signalling.33 The phosphatidylinositol
and its phosphorylated products have been shown to be the precursors
for messengers generated by phospholipases, although they have been
directly implicated in signalling.34,35 Another level of control of signal-
ling by PGs is attributed to Ca2+, which is a highly versatile intracellular
signal that modifies various cellular processes through spatial and
temporal dynamic remodelling of a variety of signalling constituents.36
Activation of EP receptors leads to changes in the production of cAMP
and/or phosphoinositol turnover and intracellular Ca2+ mobilization.32
EP1 was first described as involved in constriction of smooth
muscle.37 The C-terminal domain of the EP1 receptor binds to
Ga-q heterotrimeric guanine nucleotide-binding protein. Activation
of EP1 by ligand binding results in increased phosphatidylinositol
hydrolysis and elevation of the intracellular Ca2+ through activation of
phospholipase-C (Figure 1).
In contrast, EP2 was originally believed to have a role in smooth
muscle relaxation.38 Both EP2 and EP4 are coupled to Gs-proteins,
leading to increased production of cAMP and activation of protein
kinase A (PKA)32,39 (Figure 1). Although both receptors share the
same signalling pathway, they differ in the length of their C-terminal
sequence and hence have differing sensitivities to phosphorylation and
desensitization.40 The distinguishing feature of EP4 is, however, the
ability to activate phosphatidylinositol 3 kinase signalling pathways
following phosphorylation by G-protein coupled receptor kinases41 or
by virtue of the ability to bind Gi proteins42,43 (Figure 1). Both EP2
and EP4 are capable of stimulating the T-cell factor/lymphoid enhan-
cer factor and inhibiting glycogen synthase kinase-3 through the PKA
and phosphatidylinositol 3 kinase-dependent signalling pathways,
respectively.44
The major signalling pathway activated by EP3 receptor-ligand
binding goes through the pertussis toxin-sensitive Gi protein, resulting
in inhibition of AC and decrease in cAMP levels.45 However, EP3
receptors have different C-terminal splice variants that exhibit varied
specificities for downstream G-proteins. In this context, EP3a and
EP3b couple to Gi and inhibit AC, whereas EP3g couples to Gs in
addition to Gi, and evokes cAMP production.46,47 Moreover, EP3 has
been demonstrated to activate the small GTPase Rho in various cell
types48 (Figure 1).
A difference in the structure of the C-terminal domain of EP
receptors determines the differential nature of agonist-induced desen-
sitization and internalization. Till date, knowledge of EP1 receptor
trafficking has been limited. But with respect to EP3, the existence of
different variants generated by alternative splicing of the C-terminal
tail reflects on the variations observed in signal transduction and
intracellular trafficking. EP3a undergoes rapid agonist-induced desen-
sitization and sequestration followed by long-term downregulation,
whereas no such changes were observed in EP3b trafficking.49 The long
C-terminal of the EP4 receptor contributes to its susceptibility to rapid
agonist-induced internalization and desensitization.50,51 However, the
EP2 receptor undergoes neither rapid agonist-induced internalization
nor desensitization owing to a shorter C-terminal sequence.40,51
With respect to their tissue distribution and cellular localization, it
has been demonstrated that EP2-4 are widely distributed in almost all
mouse tissues, whereas EP1 mRNA expression is restricted to distinct
organs such as the kidney, lung and stomach. EP2 is the least
abundant of all the receptors. As each EP receptor is committed to
a defined signalling pathway and its associated function, they follow a
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restricted expression pattern within each organ system. Interestingly,
this precise cellular localization of EP receptors is found in mice,
humans and rabbits.52,53 A detailed summary of described physiolo-
gical functions of each subtype of the four EP receptors are enlisted in
supplementary Table 1.
EFFECT OF PGE2 ON T-CELL ACTIVATION AND
DIFFERENTIATION
Although most of the PGE2 secreted in the body comes from profes-
sional APCs and stromal cells, in vitro findings have shown that PTGS2
(gene for COX2) is transcriptionally upregulated in human T cells
during T cell receptor (TCR)/CD3 triggering and that it behaves as an
early inducible gene in the T-cell activation process.54
With respect to EP receptor expression, while mRNA for all types of
EP receptors were detected in murine T cells, expression of EP1 and
EP3 has not been fully documented.55 Recent studies have confirmed
that EP2 and EP4 are the main receptor subtypes to mediate the
actions of PGE2 in human and murine CD4
+ T cells.56
Immunosuppressive role of PGE2 on T-cell function
PGE2-induced activation of AC and production of cAMP and its role
in producing an inhibitory effect on T-cell activation was documented
in the early 1970s.57,58 Starting from the early 1980s, it has been
strongly believed that PGE2 has a largely immunosuppressive role to
have in T-cell activation and proliferation. Many attempts were made
to describe the working mechanism of this process. The immunomo-
dulatory role of PGE2 in T-cell activation was documented430 years
ago, when it was postulated that PGE2 concentration, as well as the
state of differentiation of the target cell, and length of PGE2–target cell
interaction were important factors controlling the process (reviewed in
Goodwin and Ceuppens59).
Initial findings reported a role of PGE2 in mediating induction of
nonspecific T lymphocyte suppressor activity,60 and a drastic inhibi-
tion of T-cell proliferation, hence modifying T-cell blastogenic
responses in mice lymphoid organs61,62 and suppressing proliferation
of lymphoma in mice.63 Later studies suggested that PGE2 primarily
exerts its inhibitory effect on lymphocyte proliferation through an
inhibition of IL-2 production.64,65 This was followed by reports that
stated that inhibition of lymphocyte response was brought about by
PGE2-producing macrophages,
66 which were found to inhibit IL-1-
dependent T-lymphocyte differentiation.67 Subsequent research sub-
stantiated the suppressive function of PGE2 in T-cell responses.
However, it was not until the late 1980s that research began to
delineate the underlying inhibitory pathways of PGE2 in T cells,
mainly through the production of cAMP. It was found that cAMP
exerts its anti-proliferative effects through interference with IL-2-
mediated gene-expression.68,69 cAMP was also shown to downregulate
transferrin receptor expression in an IL-2-dependent manner70 and
abrogate TCR-mediated cytosolic increases in Ca2+,71 later confirmed
by studies in sepsis.72 cAMP was also found to negatively regulate the
phosphoinositide cycle-related transduction pathway including inhi-
bition of phosphatidylinositol hydrolysis and diacylglycerol and
Figure 1 EP receptors: types and signalling. The four different EP receptors are high-affinity G-protein coupled receptors characterized by the activation of
different signalling pathways. EP2 and EP4 are linked to Gas proteins and function by inducing the adenylate cyclase (AC) system and concomitant
increases in the secondary messenger cAMP. cAMP acts by activating PKA, resulting in the dissociation of the regulatory and catalytic subunits of the
kinase. The catalytic subunits initiate the corresponding transactivation of the transcription factor CREB. EP4 is also capable of activating the
phosphatidylinositol 3 kinase (PI3K) signalling pathway by phosphorylation induced by G-protein-coupled receptor kinases. This ultimately results in the
triggering of NF-kB-mediated transcription programs. EP3 isoforms differ in their ability to modulate signal transduction. EP3a and EP3b are capable of
blocking induction of AC while EP3g potentiates AC and cAMP production. EP1, on the other hand, couples to Gaq protein and signals through the
phospholipase C (PLC)/inositol-1,4,5-trisphosphate (IP3) pathway resulting in the formation of the second messengers diacylglycerol (DAG) and IP3, with the
latter rapidly liberating Ca2+ ions from intracellular stores.
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inositol phosphate (IP) production.73,74 Increases in cAMP were also
found to inhibit expression of IL-2 receptors.75,76 Increasing intracel-
lular concentrations of cAMP may result in a reduction of K+
movements and in negative modulation of signal transduction via
G-proteins, impairing T-cell activation further.77
The suggestion that PGE2 might alter polarization of T helper cells
to Th1 and Th2 subtypes was demonstrated first in a study by Betz
and Fox,78 where they showed that PGE2 inhibits IL-2 and IFN-g
production (Th1) but not IL-4 and IL-5 production (Th2). This was
further re-confirmed by the demonstration that PGE2 upregulates IL-5
production in T cells.79 It was later demonstrated that while PGE2
primed Th cells to produce higher amounts of IL-4, IL-10 and IL-13,80
it was found to inhibit IL-12 production and IL-12 receptor respon-
siveness,81 consolidating its role in the Th1/Th2 balance.
On the other hand, there are various reports that suggest that PGE2
enhances induction and differentiation of FOXP3+CD4+CD25+ adap-
tive regulatory T cells that thereby suppress effector T-cell stimulation
pathways.82–84 In addition, PGE2 has been shown to induce T-cell
anergy85 to maintain the survival of CD45RO+ T cells86 and to inhibit
gd T-cell cytotoxicity triggered by the TCR through cAMP-mediated
PKA type I-dependent signalling.87
With respect to transcription factors and nuclear proteins, it was
found that cAMP signalling interfered with the activation pathway for
NF-kB,88 and counteracted calcineurin-dependent pathways.89 Yet,
decreased IL-2 production in the presence of PGE2 was shown to be
due to targeting of AP-1 and NF-AT transcription factors in human
T cells.90 Therefore, qualitative differences in the concentration of
cAMP and PKA activity can be considered as important elements in
modulating T-cell proliferative responses.91
Several molecular mechanisms have been proposed for the inhibi-
tion of T-cell activation by PGE2. PGE2 signalling has been proved to
attenuate p59(fyn) protein tyrosine kinase activity92,93 and interfere
with the protein-kinase C pathway.94,95 The enzyme Csk has been
shown to negatively regulate Lck, a kinase responsible for TCR
signalling following antigen recognition.96–99 PGE2-mediated cAMP
was also shown to regulate raft-associated Csk in a spatial and
enzymatic manner.100 It is well known that TCR ligation results in
the activation of mitogen-activated protein kinase cascades involving
different members such as ERK and p38 mitogen-activated protein
kinases. These kinases are important for regulating transcription
factors that control growth, survival and differentiation of T
cells.101,102 Hematopoietic protein tyrosine phosphatase phosphoryla-
tion by PKA in T cells and its negative regulation of extracellular
signal-regulated protein kinase and mitogen-activated protein kinase
pathways has also been reported.103 The inhibition of the kinase Lck
was also proposed as a mechanism of suppression of T-cell activation
triggered by PGE2.
104 Stimulation of prolactin expression (a negative
regulator of T-cell proliferation) was also shown to be mediated
through Ca2+ and cAMP signalling through EP3 and EP4 receptors
by PGE2 in T cells.
105
The immunosuppressive role of PGE2 in T-cell responses has been
summarized in Figure 2.
Figure 2 Negative regulation of T-cell responses by PGE2. PGE2 mediates its anti-inflammatory effects on T cells through different mechanisms: (i) PGE2 has
been shown to induce differentiation of FOXP3+CD4+CD25+ adaptive regulatory T cells that were found to inhibit effector T-cell responses, (ii) PGE2 has also
been demonstrated to suppress T-cell proliferation through different mechanisms, (iii) PGE2 is involved in the inhibition of secondary messenger generation
including the abrogation of Ca2+, K+, diacylglycerol (DAG) and IP production, (iv) T-cell anergy has been known to be promoted by high concentrations of
PGE2, (v) PGE2 favors cell survival by blocking activation-induced apoptosis, cellular cytotoxicity and caspase activation, (vi) PGE2 at micromolar
concentrations was found to be inhibitory for Th1 differentiation and beneficial for Th2 differentiation, (vii) modulation of TCR-mediated signal transduction
pathways by PGE2. (a) regulation of Csk, (b) hematopoietic protein tyrosine phosphatase (HePTP) phosphorylation by cAMP-dependent protein kinase and
promotion of prolactin expression, (c) interference of PKC signalling, (d) attenuation of p59(fyn) protein tyrosine kinase activity, (e, f) negative regulation of
extracellular signal-regulated protein kinase (ERK) and mitogen-activated protein kinase (MAPK) pathways (g) PKA-mediated signalling potentiates T-cell
factor (Tcf)/lymphoid enhancer factor (Lef) signalling pathways, (h) while PI3K inhibits glycogen synthase kinase-3 (GSK3) signal-mediation.
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Pro-inflammatory role of PGE2 in T-cell function
An indirect pro-inflammatory role for PGE2 in human T lymphocytes
was shown to be mediated by the induction of IL-8 (CXCL8) gene
transcription following activation of C/EBP homologous protein.106
IL-8 (CXCL8) thus produced by T cells was then shown to mediate
neutrophil recruitment and sustain inflammation.106 However, a
different perspective on the suppressive nature of PGE2 came into
view when it was shown that nanomolar concentrations of PGE2
potentiated Th1 and Th17 differentiation through phosphatidylinosi-
tol 3 kinase and PKA signalling, respectively, in a process mediated by
EP2 and EP4 receptors.107 Interestingly, administration of an EP4
antagonist suppressed Th1 and Th17 expansion within draining
lymph nodes in two disease models of inflammation: contact hyper-
sensitivity and experimental autoimmune encephalomyelitis.107 The
role of PGE2 in Th17 expansion was also reported by Boniface et al.,
56
who showed that PGE2 in combination with IL-1b and IL-23
promoted differentiation of Th17 cells by upregulating the IL-1bR
and IL-23R expression through the EP2/EP4–cAMP pathway. In this
elegant report, investigators propose that PGE2 promotes the devel-
opment and maturation of Th17 cells through activation of the EP2
receptor, while inhibiting IL-10 and IFN-g synthesis through the EP4
receptor in human and mouse T cells, substantiating a role for PGE2
in regulation of Th17 responses.56 PGE2 was also found to synergize
with IL-23 and increase the number of Th17 cells derived from human
CD4+CD45RO+ (memory) T cells but not from CD4+CD45RO
(naive) T cells.108 The favoring of IL-17 production and down-
modulation of IFN-g production by memory CD4+ T cells through
PGE2-mediated EP2/EP4 signalling, when present in micromolar
concentrations, was also demonstrated in another study.109 Esaki
et al.110 indicated an essential role of PGE2-EP2/EP4 signalling in
T-cell proliferation as well as IFN-g and IL-17 cytokine production
within the draining lymph nodes of mice during the course of
experimental autoimmune encephalomyelitis. The unique ability of
PGE2 to differentially modulate Th1 and Th17 differentiation at
different concentrations, could bring a new dimension to the PGE2-
mediated determination of the type of effector response and hence the
outcome of the inflammatory reaction.
On the other hand, indirect control of T-cell differentiation through
regulation of cytokine patterns produced by DCs has also been
reported. Exogenous PGE2 was found to enhance lipopolysaccah-
ride-induced IL-23 production by DCs, which could therefore pro-
mote Th17 differentiation.111,112 In addition, DCs cultured in the
presence of PGE2 enhanced the differentiation of naive T cells toward
the Th1 type.113 This was further emphasized in another report where
the addition of PGE2 and tumor necrosis factor-a for the maturation
of human monocyte-derived DCs enhanced CD4+ and CD8+ T-cell
proliferative responses, and favored Th1-type responses.114 Interest-
ingly, PGE2 was found to enhance T-cell proliferation by inducing the
co-stimulatory molecules OX40L, CD70 and 4-1BBL on DCs.28 This
study also shows that PGE2-matured DCs upregulate the expression of
OX-40L, OX-40 and CD70 on the surface of T cells, enlisting a
possible role in T-cell–T-cell interactions and sustained antigen-
specific immune responses.28
A comprehensive summary of the pro-inflammatory role of PGE2
in T-cell response is shown in Figure 3.
PGE2-based T-cell-targeted therapies for inflammatory disorders
Modulating T-cell effector functions is a promising therapeutic
approach for various diseases, owing to the multi-faceted roles of T
cells in immuno-pathogenesis of auto-immunity, allergy and human
Figure 3 Positive regulation of T-cell responses by PGE2. PGE2 has diverse pro-inflammatory effects on T cells. (a) Nanomolar physiological concentrations of
PGE2 induce phosphatidylinositol 3 kinase (PI3K)/Akt signalling pathways through the EP4 receptor that serve to promote Th1 differentiation patterns. (b) PGE2
has also been shown to potentiate Th17 differentiation through EP2-cAMP-PKA signalling pathways, primarily through (c) induction of IL-1b and IL-23 receptor
(d) PGE2 has been demonstrated to induce co-stimulatory molecules on the surface of DCs, thereby promoting T-cell proliferation. It has also been shown to
promote secretion of specific cytokines by DCs, for example, IL-12, which further directs Th1 differentiation and IL-23, which enhances Th17 polarization.
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immunodeficiency virus and parasitic infections. Given the impor-
tance of PGE2 signalling in the modulation of T-cell responses, several
reports have focused on the development of PGE2-targeted therapies
for immune disorders.
The non-steroidal anti-inflammatory drugs are a varied group of
pharmacologic compounds used for the treatment of processes of
inflammation, since the introduction of acetylsalicylic acid in 1899.
The first-generation non-steroidal anti-inflammatory drugs exert anti-
inflammatory, analgesic and antipyretic effects through the blockade
of PG synthesis via nonspecific inhibition of COX-1 and COX-2.
However, their employment as drugs over prolonged periods of time is
not favored, since they cause pronounced side effects such as gastro-
intestinal and renal toxicity.25,115–117 This has resulted in the shift of
focus of therapeutic interventions from COX enzymes to PGE2
synthases such as m-PGES-1.118
The past decade has experienced a major change in the outlook of
treatment regimens that aim to inhibit the actions of PGE2. Extensive
work on the tissue, organ and cell-specific functions of PGE2 has given
place to the generation of EP receptor antagonists and agonists, which
have already been applied in diverse experimental animal models.
Interestingly, the antagonism of EP receptors has been proved to be
efficient in ameliorating Th1 and Th17 responses, thereby proving to
be a potential treatment option for arthritis, autoimmune encephalitis
and contact hypersensitivity.108,119 EP receptor antagonists have been
employed for the inhibition of inflammatory pain hypersensitivity,
paw edema and cancer.120–124 The targeted modulation of T-cell
function by blocking or potentiating specific EP receptor signalling
pathways could thus be a revolutionary approach for the treatment of
a variety of immune dysfunction-related diseases.
However, there have been various limitations to the use of receptor
antagonists for therapy. One of them is the mild effectiveness of these
compounds as compared with non-steroidal anti-inflammatory drugs:
the reason being the inhibition of only one/two specific receptors
as opposed to the robust inhibition of all downstream PGs by COX
inhibitors. The antagonism/agonism of only one specific receptor would
not be efficient enough to potentially curtail/cure a disease state.
To complicate issues further, a lot of emphasis has been laid on the
different additive, compensatory or opposing roles of EP receptors in
a given disease setup or inflammatory condition. Therefore, it is not
advisable to design treatments based solely on the blocking or trigger-
ing of individual prostanoid receptors. Extensive study of calculated
combinations of specific agonists and antagonists will be required in
order to design efficient therapies to treat inflammatory disorders.
CONCLUSION AND REMARKS
The ‘classical’ perspective of the role of PGE2 as only an immuno-
suppressor of T-cell function has changed over the past decade. This
has been due to the description of concentration-dependent and
somewhat opposed effects in different scenarios of homeostasis and
inflammation and the interplay of signalling events generated by the
EP2 and EP4 receptors during the process of T-cell responses. The
pro-inflammatory actions of PGE2 in T cells and its promotion of
the Th1 and Th17 differentiation have been well defined over the
past few years. Determination of factors that cause the oscillation of
PGE2 from a T-cell immunosuppressor to a T-cell immunoactivator,
such as (1) local concentration of PGE2 during diverse phases of
inflammation, (2) differential use of EP receptors and signalling
pathway involved in T-cell subsets and (3) targeted effects of applica-
tion of EP receptor antagonists in different disease scenarios, would
be fundamental for the design of tailor-made therapies in infection,
inflammatory disorders and autoimmunity.
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